Quantcast
Last updated on April 19, 2014 at 9:20 EDT

Latest Merck KGaA Stories

2014-04-07 08:29:14

SEATTLE, April 7, 2014 /PRNewswire/ - Oncothyreon Inc. (NASDAQ: ONTY) today announced that Merck KGaA, Darmstadt, Germany, has initiated the international Phase 3 START2 study, which is designed to assess the efficacy and safety of the investigational MUC1 antigen-specific cancer immunotherapy tecemotide (also known as L-BLP25) in patients with unresectable, locally advanced Stage III non-small cell lung cancer (NSCLC). Merck KGaA, Darmstadt, Germany, is developing tecemotide...

2014-04-07 04:21:10

ROCKLAND, Massachusetts, April 7, 2014 /PRNewswire/ -- - First patient dosed in tecemotide Phase III trial; study recruiting across 250 sites in over 20 countries - START2 builds upon the data from the START* trial and explores the potential of tecemotide in patients with Stage III NSCLC who have demonstrated stable disease or objective response after concurrent chemoradiotherapy EMD Serono,...

2014-04-01 08:28:55

ROCKLAND, Mass., April 1, 2014 /PRNewswire/ -- EMD Serono, Inc., a subsidiary of Merck KGaA, Darmstadt, Germany, today announced the launch of the 10(th) edition of the EMD Serono Specialty Digest(TM) at the 26(th) Annual Meeting of The Academy of Managed Care Pharmacy (AMCP) in Tampa, FL. The Digest is an educational resource that provides market data on health plans' management of specialty pharmaceuticals in 2013 and identifies common trends occurring across plans. The Digest is...

2014-04-01 08:28:06

- Agreement aims to identify biomarkers relevant to future therapies in the area of Systemic Lupus Erythematosus and Lupus Nephritis ROCKLAND, Mass., April 1, 2014 /PRNewswire/ -- EMD Serono, a subsidiary of Merck KGaA, Darmstadt, Germany, today announced they have signed a research agreement with Pfizer Inc. and the Broad Institute in Cambridge, Massachusetts, U.S. The collaboration is focused on the genomic profiling of Systemic Lupus Erythematosus (SLE) and Lupus Nephritis (LN)...

2014-03-26 16:24:51

LEIDEN, The Netherlands, March 26, 2014 /PRNewswire/ -- Goal is to make treatment for schistosomiasis accessible to children under six years of age in endemic countries Brazilian Farmanguinhos, part of Fiocruz, and UK-based Simcyp are reinforcing the international non-profit Pediatric Praziquantel Consortium. The aim of the Consortium is to develop and register a new pediatric formulation against schistosomiasis for preschool-age children, a group currently lacking a...

2014-02-25 08:33:10

PHILADELPHIA, Feb. 25, 2014 /PRNewswire/ -- TransCelerate BioPharma Inc. ("TransCelerate") today announced the appointment of Annalisa Jenkins, MBBS, MRCP, Executive Vice President and Head of Global Research and Development at Merck Serono (biopharma division of Merck KGaA, Darmstadt, Germany), as Chair of its Board of Directors, effective immediately. Dr. Jenkins, who previously served as a member of the Board of Directors, will work closely with TransCelerate CEO Dr. Dalvir Gill to...

2014-02-21 16:20:52

DUBLIN, Ireland, February 21, 2014 /PRNewswire/ -- Research and Markets (http://www.researchandmarkets.com/research/rrlqjk/chromatography ) has announced the addition of the "Concise Analysis of the International Chromatography Reagents Market - Forecasts to 2018" [http://www.researchandmarkets.com/research/rrlqjk/chromatography ] report to their offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ) The market has witnessed a large number of...

2014-01-14 16:25:04

COPENHAGEN, Denmark, January 14, 2014 /PRNewswire/ -- Symphogen A/S, a private biopharmaceutical company with leadership in recombinant antibody mixtures for therapeutic use, today presented its achievements in 2013 and outlook for 2014 at JP Morgan's 32nd Annual Healthcare Conference in San Francisco, California. The presentation was made by Kirsten Drejer, CEO. Pipeline update Symphogen has continued to expand its oncology pipeline to include projects that...

2013-12-23 12:22:14

DUBLIN, Ireland, December 23, 2013 /PRNewswire/ -- Research and Markets ( http://www.researchandmarkets.com/research/ffpj56/chromatography) has announced the addition of the "2013 Report on the International Chromatography Reagents Market - Includes Forecasts to 2018" [http://www.researchandmarkets.com/research/ffpj56/chromatography ] report to their offering. <start_newscom> (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ) Various government...

2013-12-18 12:25:31

DARMSTADT, Germany, December 18, 2013 /PRNewswire/ -- - New agreement aims to translate CNIO research into new potential treatment options for cancer patients - License agreement encompasses two series of ATR inhibitors and a screening platform Merck Serono, the biopharmaceutical division of Merck, today announced that a license agreement has been signed with the Spanish National Cancer Research Centre (CNIO) in Madrid in the...